{"organizations": [], "uuid": "4d4c663cecf8c193a08a16178c97472a32c9c3cf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-nektar-therapeutics-announces-init/brief-nektar-therapeutics-announces-initiation-of-phase-1b-clinical-study-of-nktr-358-idUSFWN1SF0RP", "country": "US", "domain_rank": 408, "title": "BRIEF-Nektar Therapeutics Announces Initiation Of Phase 1B Clinical Study Of NKTR-358", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-08T15:53:00.000+03:00", "replies_count": 0, "uuid": "4d4c663cecf8c193a08a16178c97472a32c9c3cf"}, "author": "", "url": "https://www.reuters.com/article/brief-nektar-therapeutics-announces-init/brief-nektar-therapeutics-announces-initiation-of-phase-1b-clinical-study-of-nktr-358-idUSFWN1SF0RP", "ord_in_thread": 0, "title": "BRIEF-Nektar Therapeutics Announces Initiation Of Phase 1B Clinical Study Of NKTR-358", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "nektar therapeutics", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "nektar therapeutics", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8, 2018 / 12:55 PM / Updated 22 minutes ago BRIEF-Nektar Therapeutics Announces Initiation Of Phase 1B Clinical Study Of NKTR-358 Reuters Staff 1 Min Read\nMay 8 (Reuters) - Nektar Therapeutics:\n* NEKTAR THERAPEUTICS ANNOUNCES INITIATION OF A PHASE 1B CLINICAL STUDY OF NKTR-358, A FIRST-IN-CLASS REGULATORY T CELL STIMULATOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-08T15:53:00.000+03:00", "crawled": "2018-05-08T16:24:25.042+03:00", "highlightTitle": ""}